A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants

Inclusion Criteria: * Participants' parent(s)/ Legally acceptable representative (LAR), who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * Written or witnessed/thumb printed informed consent obtained from the parent(s)/LAR(s) of the participant prior to performance of any study specific procedure. * Healthy participants as established by medical history, clinical examination, and laboratory assessment. * Participants satisfying all screening requirements. * Participants seronegative for hepatitis B, and hepatitis C. * A male or female 9 months of age at the time of the first study intervention administration. * Normal nutritional z-score. * Previously completed routine childhood vaccinations to the best knowledge of the participant's parent(s)/LAR(s). * Born at a gestation period of \>=37 weeks to the best knowledge of the participant's parent(s)/LAR(s). * Participants negative for human immunodeficiency virus as confirmed by DNA polymerase chain reaction testing. * Participants negative for HLA-B27. Exclusion Criteria: * Known exposure to Shigella during lifetime of the participant as confirmed during interview with the participant's parent(s)/LAR(s) or documented by participant's records. * Progressive, unstable, or uncontrolled clinical conditions. * History (known or suspected) of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention. * Major congenital defects, as assesse…